Sort
51,593 grants matching “hepatitis”
Mechanisms of Altered Hepatic Drug Metabolism and Transport in Pregnancy
$407,747Craig R Lee · Univ Of North Carolina Chapel Hill · R01 · FY2021 · HD
Novel Pathogen Recognition Pathways and Control of Hepatitis A Virus
$407,732Stanley M Lemon · Univ Of North Carolina Chapel Hill · U19 · FY2017 · AI
Novel Pathogen Recognition Pathways and Control of Hepatitis A Virus
$407,731Stanley M Lemon · Univ Of North Carolina Chapel Hill · U19 · FY2016 · AI
Novel Pathogen Recognition Pathways and Control of Hepatitis A Virus
$407,731Stanley M Lemon · Univ Of North Carolina Chapel Hill · U19 · FY2014 · AI
Rapid Motion-Robust and Easy-to-Use Dynamic Contrast-Enhanced MRI for Liver Perfusion Quantification
$407,721Li Feng · New York University School Of Medicine · R01 · FY2023 · EB
Multiple Tumor Antigen-loaded DC Vaccine for Hepatocellular Cancer
$407,715Lisa Helene Butterfield · University Of Pittsburgh At Pittsburgh · R01 · FY2012 · CA
RESEARCH PROJECT 1: Chemical and Viral Biomarkers of Exposure and Risk (Groopman)
$407,684John D Groopman · Johns Hopkins University · P01 · FY2012 · ES
HEPATIC RF ABLATION: DEVELOPMENT OF EFFECTIVE DEVICES
$407,656University Of Wisconsin Madison · R01 · FY2005 · DK
ROLE OF ENZYME INDUCTION IN CANCER CHEMOPREVENTION
$407,645Thomas W Kensler · Johns Hopkins University · R01 · FY2007 · CA
T Cells To AAV And AAV-Encoded Transgene Products
$407,635Hildegund C. J. Ertl · Wistar Institute · P01 · FY2012 · HL
Altering Hepatitis B Virus assembly through pharmacological intervention
$407,510James C. Gumbart · Georgia Institute Of Technology · R01 · FY2020 · AI
Cellular Mechanisms of Hepatotoxicity.
$407,500Neil Kaplowitz · University Of Southern California · R01 · FY2011 · DK
Insulin action, reverse cholesterol transport, and HDL function
$407,475Rebecca Anne Haeusler · Columbia University Health Sciences · R01 · FY2018 · HL
Anticancer Drug Pharmacology in Very Young Children
$407,467Clinton F Stewart · St. Jude Children'S Research Hospital · R01 · FY2013 · CA
OPTIMIZATION OF A BIOARTIFICIAL LIVER-PHASE II
$407,467Algenix, Inc. · R44 · FY2001 · DK
Regulation of drug metabolizing enzymes by miRNAs
$407,458Todd C. Skaar · Indiana University Indianapolis · R01 · FY2010 · GM
Collaborative Integration of Hepatitis B Molecular Virology and Mathematical/Computational Modeling
$407,382Susan L Uprichard · Loyola University Chicago · R01 · FY2023 · AI
Viral Host Interactions in Hepatitis C
$407,380David Richard Gretch · University Of Washington · R01 · FY2007 · AI
Role of the Gut Microbiota and TLR4 in Alcoholic Hepatocarcinogenesis
$407,378Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2012 · AA
Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis
$407,297Phyllis C Tien · Northern California Institute/Res/Edu · R01 · FY2013 · AI
Precise image guidance for liver cancer stereotactic body radiotherapy using element-resolved motion-compensated cone beam CT
$407,275Xun Jia · Ut Southwestern Medical Center · R01 · FY2018 · CA
Biological Roles of Factors X and Xa
$407,264Katherine A High · Children'S Hosp Of Philadelphia · P01 · FY2007 · HL
CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PHASEI/II TRIAL OF A THERAPEUTIC DNA VACCINE FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION;HHSN261201200042I; TASK ORDER HHSN26100006; 09/09/2014 09/08/2016
$407,260Paul J Limburg · Mayo Clinic Rochester · N01 · FY2014 · CA
The Role of HMGB1 in autophagy deficiency-induced liver pathology
$407,228Xiao-Ming Yin · Tulane University Of Louisiana · R01 · FY2020 · DK
The budding yeast endocytic pathway
$407,219David G. Drubin · University Of California Berkeley · R01 · FY2013 · GM